Clinical Ink: new executive hires
Trial tech provider Clinical Ink has announced a number of new appointments, all reportedly brought on to manage demand for Lunexis, its eCOA, ePRO+, DDC and eConsent platform. The recently added staff include:
- Bill Barrasso, vice president
- Chris Crucitti, chief commercial officer
- Brian Donahue, chief commercial officer
Clinical Ink CEO Ed Seguine said of the new hires, “This industry is plagued with visionary talk that so often lacks substance and comes up short in real-life … These leaders bring great insight, expertise, and vision to our confident, reliable delivery of results in the most complex and demanding therapeutic areas.”
